Kirsten E Lyke, Joel V Chua, Michael Koren, Heather Friberg, Gregory D Gromowski, Rekha R Rapaka, Adam T Waickman, Sudhaunshu Joshi, Kathleen Strauss, Michael K McCracken, Hernando Gutierrez-Barbosa, Biraj Shrestha, Christopher Culbertson, Paula Bernal, Rafael A De La Barrera, Jeffrey R Currier, Richard G Jarman, Robert Edelman
BACKGROUND: Dengue human infection models (DHIMs) are important tools to down-select dengue vaccine candidates and establish tetravalent efficacy before advanced clinical field trials. We aimed to provide data for the safety and immunogenicity of DHIM and evaluate dengue vaccine efficacy. METHODS: We performed an open-label, phase 1 trial at the University of Maryland (Baltimore, MD, USA). Eligible participants were healthy individuals aged 18-50 years who either previously received a tetravalent dengue purified inactivated vaccine prime followed by a live-attenuated vaccine boost (ie, the vaccinee group), or were unvaccinated flavivirus-naive participants (ie, the control group)...
April 25, 2024: Lancet Infectious Diseases